1-4 of 4
radionuclide therapy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Jarrod Longcor, Kate Oliver, BS
Journal: Blood
Blood (2019) 134 (Supplement_1): 1864.
https://doi.org/10.1182/blood-2019-131806
Published: 2019
Journal Articles

First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131 I-Rituximab: The INITIAL Study,

Andrew D McQuillan, MBBS FRACP FRCPA, William BG Macdonald, MBBS FRACP, Michael F Leahy, J Harvey Turner, MD FRACP
Journal: Blood
Blood (2011) 118 (21): 3719.
https://doi.org/10.1182/blood.V118.21.3719.3719
Published: 2011
Journal Articles

Fully human monoclonal antibodies and targeted radionuclide therapy

Tod W. Speer
Journal: Blood
Blood (2008) 112 (6): 2584–2585.
https://doi.org/10.1182/blood-2008-06-163600
Published: 2008
Journal Articles

PS-341 Induces Selective Radiosensitization of Multiple Myeloma Cells.

Apollina Goel, Ph.D., Angela Dispenzieri, M.D., Philip R. Greipp, M.D., Thomas E. Witzig, M.D., Ruben A. Mesa, M.D., Stephen J. Russell, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2478.
https://doi.org/10.1182/blood.V104.11.2478.2478
Published: 2004